News

PIR International Free Webinar - Five Ways to Develop Life Science Leaders to Improve Global Healthcare

The world's focus on healthcare and leadership has never been greater. COVID-19 has led us to place higher value on our health, and question what makes a good leader, in times of crisis and in securing our future.

The Life Sciences industry is somewhat unique, in that it has the power to influence both.

For those working in it, it is a challenging industry with high expectations. To manage a growing ageing population and continuously evolving healthcare needs, the life sciences industry needs innovative, high performing, happy and healthy leaders.

Stevenage Bioscience Catalyst announces Professor Jackie Hunter as new Chair

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020.

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.

Horizon Discovery Group plc Results for the Six Months Ended 30 June 2020

Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020.

Group Financial Highlights

BioIVT Offers Expedited Delivery of Immune Cell Products for Cell and Gene Therapy Research, Drug Discovery and Diagnostic Development

Westbury, NY – Aug. 14, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is now offering same- or next-day delivery of fresh blood and immune cell products from its seven blood donor centers, which are strategically located near biopharma hubs in the US and UK, to almost anywhere in the world.

COVID-19: Potential Vaccines and Logistics

While pharmaceuticals contribute to approximately 2% of annual air cargo volume, the industry transports over one trillion dollars’ worth of cargo every year (IATA). Pharmaceutical shipments have an overwhelmingly large impact on the global response to infectious diseases and general healthcare.

COVID-19 has shown that effective healthcare logistics management requires not only regulatory expertise and extensive planning, but also a proactive global network of logistics experts who can respond to last-minute changes, namely flight cancellations and lockdowns.

CRISPR-based screening technology platform to address critical gaps in target ID and validation

Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight

Inventive use of space allows Diagnostics for the Real World to keep on top of demand for COVID-19 test kits

Chesterford Research Park management team and Diagnostics for the Real World work together, re-purposing space to create efficient assembly line

£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park

Science Park helping to drive local economic growth with SELEP support

Richmond Research Institute – COVID-19 Response & Community Testing

Situation:

The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.

Our position:

My Account